• Login
• Admin

Onida, Francesco, De Wreede, Lliesbeth C., van Blezan, Anja, Elkema, Diderik-Jan, Byrne, Jenny L., Iori, Anna P., Schots, Rick, Jungova, Alexandra, Schetelig, Johannes, Finke, Juergen, Veelken, Hendrick, Johanssen, Jan-Erik, Craddock, Charles, Stellies, Matthias, Theobald, Matthias, Holler, Ernst, Schanz, Urs, Schaap, Nicolaas, Bittenbring, Joerg, Olivaria, Eduardo, Chalandan, Yves and Kroger, Nicolaus (2017) Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 177 (5). pp. 759-765. ISSN 2836-9779

Full text not available from this repository.

Abstract

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were ‘low-risk’, 31% ‘intermediate-risk’ and 24% ‘high-risk’. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

Item Type:	Article
RIS ID:	https://nottingham-repository.worktribe.com/output/863277
Additional Information:	This is the pre-peer reviewed version of the following article:Onida, F., de Wreede, L. C., van Biezen, A., Eikema, D.-J., Byrne, J. L., Iori, A. P., Schots, R., Jungova, A., Schetelig, J., Finke, J., Veelken, H., Johansson, J.-E., Craddock, C., Stelljes, M., Theobald, M., Holler, E., Schanz, U., Schaap, N., Bittenbring, J., Olavarria, E., Chalandon, Y., Kröger, N. and the Myeloproliferative Neoplasm Subcommittee of the Chronic Malignancies Working Party (2017), Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol, 177: 759–765. doi:10.1111/bjh.14619, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bjh.14619/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving
Keywords:	allogeneic transplantation, atypical chronic myeloid leukaemia, Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN), Ph-negative CML:BCR-ABL1-negative
Schools/Departments:	University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Cancer and Stem Cells
Identification Number:	doi: 10.1111/bjh.14619
Depositing User:	Byrne, Jenny
Date Deposited:	14 Dec 2017 11:12
Last Modified:	04 May 2020 18:48
URI:	https://eprints.nottingham.ac.uk/id/eprint/48728

Actions (Archive Staff Only)

Edit View